Why the study?
Thyrotoxicosis-induced dilated cardiomyopathy is a rare but potentially life-threatening complication that can cause irreversible changes in cardiac structure and function if left untreated.
Population
One 39-year-old patient with thyrotoxicosis-induced acute heart failure
Design
Case report
Key result
Methimazole, metoprolol, and sacubitril/valsartan therapy successfully reversed thyrotoxicosis-induced dilated cardiomyopathy, improving the patient's ejection fraction from 36% to 56%.
Authors
Loading...
May support combined antithyroid and GDMT for thyrotoxic cardiomyopathy; leaves open generalizability pending controlled trials.
Case Report (n=1)
No
Prompt intensive treatment of thyrotoxicosis-induced cardiomyopathy with anti-thyroid and heart failure medications can rapidly reverse severe left ventricular systolic dysfunction.
Khalil et al. (2023) conducted a case report in Thyrotoxicosis-induced dilated cardiomyopathy (n=1). Methimazole, metoprolol, and sacubitril/valsartan was evaluated on Left ventricular ejection fraction. Methimazole, metoprolol, and sacubitril/valsartan therapy successfully reversed thyrotoxicosis-induced dilated cardiomyopathy, improving the patient's ejection fraction from 36% to 56%.